|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 9/20 | (2006.01) |
| A61K 31/517 | (2006.01) | ||
| A61K 9/28 | (2006.01) | ||
| C07D 405/04 | (2006.01) |
| (11) | Number of the document | 1871347 |
| (13) | Kind of document | T |
| (96) | European patent application number | 06750475.3 |
| Date of filing the European patent application | 2006-04-18 | |
| (97) | Date of publication of the European application | 2008-01-02 |
| (45) | Date of publication and mention of the grant of the patent | 2016-08-03 |
| (46) | Date of publication of the claims translation | 2016-11-10 |
| (86) | Number | PCT/US2006/014447 |
| Date | 2006-04-18 |
| (87) | Number | WO 2006/113649 |
| Date | 2006-10-26 |
| (30) | Number | Date | Country code |
| 672805 P | 2005-04-19 | US |
| (72) |
CARTER, Barry Howard, GlaxoSmithKline Corp. Int., US
CAMPBELL, Dwayne A., GlaxoSmithKline Corp. Int., US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Farmacinė kompozicija |
| PHARMACEUTICAL COMPOSITION |
| Payment date | Validity (years) | Amount | |
| 2020-04-04 | 15 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2021-04-18 |